Regeneron’s Billion-Dollar Catalyst Flying Under Wall Street’s Radar Ahead of Oct. 30 Earnings
Regeneron reports earnings on Oct. 30, and a quiet accounting change tied to its Sanofi partnership may finally reveal what Dupixent is actually worth to the bottom line. Most of Wall Street has barely noticed.
Regeneron (NASDAQ:REGN | REGN Price Prediction) reports third-quarter results on Oct. 30. Regeneron books its full share of Dupixent profits from Sanofi (NASDAQ:SNY) for the first time this quarter. I think that change matters more than the market is giving it credit for.
Dupixent’s Billion-Dollar Profit Drag Is Gone
Last quarter, Regeneron posted non-GAAP EPS of $14.29 against an $8.00 consensus. Revenue rose 16.73% to $4.29 billion, and global Dupixent sales reached $6.00 billion, up 38%.
On the conference call, management said Regeneron has fully returned the Sanofi development balance, which stood at about $3.1 billion when the agreement was amended in 2022. Repayments cut reported collaboration revenue by roughly $930 million in 2025 and $530 million in the first half of this year. Management expects collaboration revenue to step up beginning in the third quarter.
Since then, the two partners announced an expanded alliance worth up to $8 billion. The deal brings four long-acting antibodies and settles prior litigation between the companies. Shares trade near $815, up 42.28% over the past year.
Analysts Already Expect a Sharp Step-Up
| Metric | Consensus | Prior-Year Actual | Implied YoY Growth |
|---|---|---|---|
| Q3 2026 Normalized EPS | $16.198 | $11.83 | 36.9% |
| Q3 2026 Revenue | $4.56 billion | $3.75 billion | 21.5% |
| FY 2026 EPS | $59.1298 | $44.31 | 33.4% |
| FY 2026 Revenue | $17.60 billion | $14.34 billion | 22.7% |
The quarterly EPS estimate stood at $13.2058 90 days ago, so analysts have partly priced in the Sanofi change.
Collaboration Margins and Eylea HD Will Set the Tone
My first focus is the size of the collaboration step-up. Management expects second-half Dupixent growth to remain strong but moderate against harder comparisons. That means the jump in Regeneron’s share needs to come from the cleaner profit split, and the quarter will reveal the extent of it.
Eylea HD is the second test. U.S. sales hit $596 million last quarter, up 52%, and passed legacy Eylea for the first time. Management guided to sequential HD demand growth in the low to mid-teens, while legacy Eylea demand falls by a similar rate. You should look for any update on the prefilled syringe, which management hopes to get approved before the end of the year.
Margins matter too. Limerick production returned to normal by the end of the second quarter, and Regeneron raised GAAP gross margin guidance to 78%-79%. Launch plans for cemdisiran also deserve attention ahead of its November 2026 FDA target action date. Drug-pricing policy remains a risk that could weigh on top-selling biologics.
First Clean Look at Dupixent’s True Earnings Power
For years, repayment of the development balance hid how much Dupixent actually adds to Regeneron’s earnings. This quarter gives investors the first clear read on that number. If Eylea HD continues outpacing the decline in legacy Eylea, Regeneron enters 2027 with its growth engine running at full strength. That is the setup I’ll be measuring against the upcoming results.
Contact [email protected] for any questions or corrections.
After two decades of patrolling the dark corners of suburbia as a police officer, Rich Duprey hung up his badge and gun to begin writing full time about stocks and investing. For the past 20 years, he’s been cruising the markets looking for companies to lock up as long-term holdings in a portfolio while writing extensively on the broad sectors of consumer goods, technology, and industrials. Because his experience isn’t from the typical financial analyst track, Rich is able to break down complex topics into understandable and useful action points for the average investor. His writings have appeared on The Motley Fool, InvestorPlace, Yahoo! Finance, Money Morning, and, of course, 24/7 Wall St. He has been featured in both U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, and USA Today.
